C.M. Pirie

FDA guidelines and animal models for osteoporosis

David D. Thompson, Hollis A. Simmons, C.M. Pirie et al. · Bone · 1995 · 523 citations

Bone Disease, Bone Health, Fda Guidelines +3

Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models

Hua Zhu Ke, Vishwas Paralkar, W A Grasser et al. · Endocrinology · 1998 · 157 citations

Gynecology, Rat Models, Female Reproductive Function +17

Discovery and Preclinical Pharmacology of a Novel, Potent, Nonsteroidal Estrogen Receptor Agonist/Antagonist, CP-336156, a Diaryltetrahydronaphthalene

Robert L. Rosati, Paul Da Silva Jardine, Kimberly O. Cameron et al. · Journal of Medicinal Chemistry · 1998 · 131 citations · Full text

Molecular Pharmacology, Medicine, Hormonal Receptor +15

Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model

Hua Zhu Ke, H.K. Chen, Hollis A. Simmons et al. · Bone · 1997 · 122 citations

Hormonal Contraceptive, Serum Cholesterol, Medicine +10

Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.

H.Z. Ke, Hollis A. Simmons, C.M. Pirie et al. · Endocrinology · 1995 · 114 citations

Gynecology, Pharmacotherapy, Osteoporosis +17